Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Yale J Biol Med ; 88(2): 181-5, 2015 Jun.
Article in English | MEDLINE | ID: mdl-26029016

ABSTRACT

Li-Fraumeni syndrome is a rare cancer predisposition syndrome classically associated with remarkably early onset of cancer in families with a typical spectrum of malignancies, including sarcoma, breast cancer, brain tumors, and adrenocortical carcinoma. Because the risks of cancer development are strikingly high for Li-Fraumeni syndrome, aggressive cancer surveillance is often pursued in these individuals. However, optimal screening methods and intervals for Li-Fraumeni syndrome have yet to be determined. In addition, there may be a significant psychosocial burden to intensive cancer surveillance and some prevention modalities. Here, we describe a case of a young woman with a de novo mutation in TP53 and multiple malignancies, with her most recent cancers found at early, curable stages due to aggressive cancer screening. The potential benefits and risks of intensive cancer surveillance in hereditary cancer syndromes is discussed.


Subject(s)
Early Detection of Cancer/methods , Li-Fraumeni Syndrome/diagnosis , Li-Fraumeni Syndrome/genetics , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/genetics , Child , Female , Genetic Predisposition to Disease/genetics , Humans , Li-Fraumeni Syndrome/therapy , Neoplasms, Multiple Primary/therapy , Treatment Outcome
2.
Clin Transl Gastroenterol ; 12(8): e00397, 2021 08 16.
Article in English | MEDLINE | ID: mdl-34397043

ABSTRACT

INTRODUCTION: Uninformative germline genetic testing presents a challenge to clinical management for patients suspected to have Lynch syndrome, a cancer predisposition syndrome caused by germline variants in the mismatch repair (MMR) genes or EPCAM. METHODS: Among a consecutive series of MMR-deficient Lynch syndrome spectrum cancers identified through immunohistochemistry-based tumor screening, we investigated the clinical utility of tumor sequencing for the molecular diagnosis and management of suspected Lynch syndrome families. MLH1-deficient colorectal cancers were prescreened for BRAF V600E before referral for genetic counseling. Microsatellite instability, MLH1 promoter hypermethylation, and somatic and germline genetic variants in the MMR genes were assessed according to an established clinical protocol. RESULTS: Eighty-four individuals with primarily colorectal (62%) and endometrial (31%) cancers received tumor-normal sequencing as part of routine clinical genetic assessment. Overall, 27% received a molecular diagnosis of Lynch syndrome. Most of the MLH1-deficient tumors were more likely of sporadic origin, mediated by MLH1 promoter hypermethylation in 54% and double somatic genetic alterations in MLH1 (17%). MSH2-deficient, MSH6-deficient, and/or PMS2-deficient tumors could be attributed to pathogenic germline variants in 37% and double somatic events in 28%. Notably, tumor sequencing could explain 49% of cases without causal germline variants, somatic MLH1 promoter hypermethylation, or somatic variants in BRAF. DISCUSSION: Our findings support the integration of tumor sequencing into current Lynch syndrome screening programs to improve clinical management for individuals whose germline testing is uninformative.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , DNA Mismatch Repair , Germ-Line Mutation , Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis , DNA Methylation , Epithelial Cell Adhesion Molecule/genetics , Female , Humans , Male , Microsatellite Instability , Middle Aged , MutL Protein Homolog 1/genetics
3.
Cancer J ; 20(4): 246-53, 2014.
Article in English | MEDLINE | ID: mdl-25098283

ABSTRACT

After repeated media attention in 2013 due to the Angelina Jolie disclosure and the Supreme Court decision to ban gene patents, the demand for cancer genetic counseling and testing services has never been greater. Debate has arisen regarding who should provide such services and the quality of genetics services being offered. In this ongoing case series, we document 35 new cases from 7 states (California, Connecticut, Florida, Georgia, Missouri, Pennsylvania, and Utah) and the District of Columbia of adverse outcomes in cancer genetic testing when performed without the involvement of a certified genetic counselor. We identified 3 major themes of errors: wrong genetic tests ordered, genetic test results misinterpreted, and inadequate genetic counseling. Patient morbidity and mortality were an issue in several of these cases. The complexity of cancer genetic testing and counseling has grown exponentially with the advent of multigene panels that include rare genes and the potential for more variants of uncertain significance. We conclude that genetic counseling and testing should be offered by certified genetics providers to minimize the risks, maximize the benefits, and utilize health care dollars most efficiently.


Subject(s)
Neoplasms/diagnosis , Neoplasms/genetics , Adult , Aged , Delivery of Health Care/economics , Delivery of Health Care/methods , Female , Genetic Counseling/economics , Genetic Counseling/methods , Genetic Testing/economics , Genetic Testing/methods , Humans , Male , Middle Aged , Neoplasms/economics , Risk Assessment/economics , Risk Assessment/methods , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL